PIPELINE
TP-317 is being developed as an oral therapy for diseases with high unmet need
Pipeline
TP-317 offers multiple pipeline opportunities based on its unique mechanism of action as an agonist of BLT1 that promotes immune homeostasis.
This approach targets key aspects of disease progression in IBD and cancer that are not adequately addressed by other drug classes.
Inflammatory Bowel Disease
Unmet Medical Need: The majority of accepted oral and biologic treatments for IBD function by suppressing the immune system. While effective for some patients, this approach often comes with elevated risk of serious infection, malignancy, or other side effects. Furthermore, many current therapeutic options prove beneficial for only a subset of patients, and among those who initially respond, long-term remission is frequently difficult to maintain. This underscores the ongoing challenges in IBD management and the need for novel treatment strategies.
Unique Barrier Protective Mechanism: TP-317 has shown distinctive potential in preclinical studies by enhancing intestinal barrier function, controlling inflammation, and promoting immune homeostasis.
Clinical Opportunities: Based on this unique profile, TP-317 is being developed as first-line oral therapy for moderate-to-severe Crohn’s disease and as second-line oral therapy for patients with moderate-to-severe ulcerative colitis who are not adequately managed with existing treatments.
Solid Tumor Cancers
Unmet Medical Need: Patients with advanced solid tumors generally face poor prognoses and limited treatment options, particularly in tumors that are resistant to immune checkpoint inhibitors.
Promoting Antigen Presentation: In preclinical tumor models, TP-317 has been shown to enhance antigen presentation machinery that drives robust single-agent efficacy in colorectal cancer, lung cancer, melanoma and pancreatic cancer. When combined with immunotherapy or chemotherapy, TP-317 exhibited enhanced anti-tumor effects, indicating potential synergistic benefits that could improve patient outcomes.
Clinical Opportunities: Based on these data, TP-317 is being developed as a complementary treatment to standard therapies for advanced solid tumors, with a focus on colorectal cancer and NSCLC. Our research also suggests TP-317 may be beneficial when used as treatment before or during surgery or radiation therapy and as maintenance therapy to help sustain remission after initial treatment.
Expanded Access
Thetis does not currently offer an expanded access program for TP-317. Patients are encouraged to speak with their physicians about treatment options that may be right for them.